Cargando…

Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

OBJECTIVE: To compare immediate initiation with delayed initiation of medication abortion among patients with an undesired pregnancy of unknown location. METHODS: This retrospective cohort study used electronic medical record data from the Planned Parenthood League of Massachusetts (2014–2019) for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Alisa B., Fulcher, Isabel R., Fortin, Jennifer, Hofer, Rebecca K., Cottrill, Alex, Dethier, Divya, Gilbert, Allison, Janiak, Elizabeth, Roncari, Danielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015019/
https://www.ncbi.nlm.nih.gov/pubmed/35576336
http://dx.doi.org/10.1097/AOG.0000000000004756
_version_ 1784688296136278016
author Goldberg, Alisa B.
Fulcher, Isabel R.
Fortin, Jennifer
Hofer, Rebecca K.
Cottrill, Alex
Dethier, Divya
Gilbert, Allison
Janiak, Elizabeth
Roncari, Danielle
author_facet Goldberg, Alisa B.
Fulcher, Isabel R.
Fortin, Jennifer
Hofer, Rebecca K.
Cottrill, Alex
Dethier, Divya
Gilbert, Allison
Janiak, Elizabeth
Roncari, Danielle
author_sort Goldberg, Alisa B.
collection PubMed
description OBJECTIVE: To compare immediate initiation with delayed initiation of medication abortion among patients with an undesired pregnancy of unknown location. METHODS: This retrospective cohort study used electronic medical record data from the Planned Parenthood League of Massachusetts (2014–2019) for patients who requested medication abortion with a last menstrual period (LMP) of 42 days or less and pregnancy of unknown location (no gestational sac) on initial ultrasonogram. Clinicians could initiate medication abortion with mifepristone followed by misoprostol while simultaneously excluding ectopic pregnancy with serial serum human chorionic gonadotropin (hCG) testing (same-day-start group) or establish a diagnosis with serial hCG tests and repeat ultrasonogram before initiating treatment (delay-for-diagnosis group). We compared primary safety outcomes (time to diagnosis of pregnancy location [rule out ectopic], emergency department visits, adverse events, and nonadherence with follow-up) between groups. We also reported secondary efficacy outcomes: time to complete abortion, successful medication abortion (no uterine aspiration), and ongoing pregnancy. RESULTS: Of 5,619 medication abortion visits for patients with an LMP of 42 days or less, 452 patients had pregnancy of unknown location (8.0%). Three patients underwent immediate uterine aspiration, 55 had same-day start, and 394 had delay for diagnosis. Thirty-one patients (7.9%), all in the delay-for-diagnosis group, were treated for ectopic pregnancy, including four that were ruptured. Among patients with no major ectopic pregnancy risk factors (n=432), same-day start had shorter time to diagnosis (median 5.0 days vs 9.0 days; P=.005), with no significant difference in emergency department visits (adjusted odds ratio [aOR] 0.90, 95% CI 0.43–1.88) or nonadherence with follow-up (aOR 0.92, 95% CI 0.39–2.15). Among patients who proceeded with abortion (n=270), same-day start had shorter time to complete abortion (median 5.0 days vs 19.0 days; P<.001). Of those who had medication abortion with known outcome (n=170), the rate of successful medication abortion was lower (85.4% vs 96.7%; P=.013) and the rate of ongoing pregnancy was higher (10.4% vs 2.5%; P=.041) among patients in the same-day-start group. CONCLUSION: In patients with undesired pregnancy of unknown location, immediate initiation of medication abortion is associated with more rapid exclusion of ectopic pregnancy and pregnancy termination but lower abortion efficacy.
format Online
Article
Text
id pubmed-9015019
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-90150192022-04-20 Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location Goldberg, Alisa B. Fulcher, Isabel R. Fortin, Jennifer Hofer, Rebecca K. Cottrill, Alex Dethier, Divya Gilbert, Allison Janiak, Elizabeth Roncari, Danielle Obstet Gynecol Contents OBJECTIVE: To compare immediate initiation with delayed initiation of medication abortion among patients with an undesired pregnancy of unknown location. METHODS: This retrospective cohort study used electronic medical record data from the Planned Parenthood League of Massachusetts (2014–2019) for patients who requested medication abortion with a last menstrual period (LMP) of 42 days or less and pregnancy of unknown location (no gestational sac) on initial ultrasonogram. Clinicians could initiate medication abortion with mifepristone followed by misoprostol while simultaneously excluding ectopic pregnancy with serial serum human chorionic gonadotropin (hCG) testing (same-day-start group) or establish a diagnosis with serial hCG tests and repeat ultrasonogram before initiating treatment (delay-for-diagnosis group). We compared primary safety outcomes (time to diagnosis of pregnancy location [rule out ectopic], emergency department visits, adverse events, and nonadherence with follow-up) between groups. We also reported secondary efficacy outcomes: time to complete abortion, successful medication abortion (no uterine aspiration), and ongoing pregnancy. RESULTS: Of 5,619 medication abortion visits for patients with an LMP of 42 days or less, 452 patients had pregnancy of unknown location (8.0%). Three patients underwent immediate uterine aspiration, 55 had same-day start, and 394 had delay for diagnosis. Thirty-one patients (7.9%), all in the delay-for-diagnosis group, were treated for ectopic pregnancy, including four that were ruptured. Among patients with no major ectopic pregnancy risk factors (n=432), same-day start had shorter time to diagnosis (median 5.0 days vs 9.0 days; P=.005), with no significant difference in emergency department visits (adjusted odds ratio [aOR] 0.90, 95% CI 0.43–1.88) or nonadherence with follow-up (aOR 0.92, 95% CI 0.39–2.15). Among patients who proceeded with abortion (n=270), same-day start had shorter time to complete abortion (median 5.0 days vs 19.0 days; P<.001). Of those who had medication abortion with known outcome (n=170), the rate of successful medication abortion was lower (85.4% vs 96.7%; P=.013) and the rate of ongoing pregnancy was higher (10.4% vs 2.5%; P=.041) among patients in the same-day-start group. CONCLUSION: In patients with undesired pregnancy of unknown location, immediate initiation of medication abortion is associated with more rapid exclusion of ectopic pregnancy and pregnancy termination but lower abortion efficacy. Lippincott Williams & Wilkins 2022-05 2022-04-05 /pmc/articles/PMC9015019/ /pubmed/35576336 http://dx.doi.org/10.1097/AOG.0000000000004756 Text en © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Contents
Goldberg, Alisa B.
Fulcher, Isabel R.
Fortin, Jennifer
Hofer, Rebecca K.
Cottrill, Alex
Dethier, Divya
Gilbert, Allison
Janiak, Elizabeth
Roncari, Danielle
Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location
title Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location
title_full Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location
title_fullStr Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location
title_full_unstemmed Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location
title_short Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location
title_sort mifepristone and misoprostol for undesired pregnancy of unknown location
topic Contents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015019/
https://www.ncbi.nlm.nih.gov/pubmed/35576336
http://dx.doi.org/10.1097/AOG.0000000000004756
work_keys_str_mv AT goldbergalisab mifepristoneandmisoprostolforundesiredpregnancyofunknownlocation
AT fulcherisabelr mifepristoneandmisoprostolforundesiredpregnancyofunknownlocation
AT fortinjennifer mifepristoneandmisoprostolforundesiredpregnancyofunknownlocation
AT hoferrebeccak mifepristoneandmisoprostolforundesiredpregnancyofunknownlocation
AT cottrillalex mifepristoneandmisoprostolforundesiredpregnancyofunknownlocation
AT dethierdivya mifepristoneandmisoprostolforundesiredpregnancyofunknownlocation
AT gilbertallison mifepristoneandmisoprostolforundesiredpregnancyofunknownlocation
AT janiakelizabeth mifepristoneandmisoprostolforundesiredpregnancyofunknownlocation
AT roncaridanielle mifepristoneandmisoprostolforundesiredpregnancyofunknownlocation